Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology-Reference-Cited by-同舟云学术

Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Published:2021-11 Issue:11 Volume:19 Page:1277-1303
ISSN:1540-1405
Container-title:Journal of the National Comprehensive Cancer Network
language:
Short-container-title:

Author:

Go Ronald S.¹,Jacobsen Eric²,Baiocchi Robert³,Buhtoiarov Ilia⁴,Butler Erin B.⁵,Campbell Patrick K.⁶,Coulter Don W.⁷,Diamond Eli⁸,Flagg Aron⁹,Goodman Aaron M.¹⁰,Goyal Gaurav¹¹,Gratzinger Dita¹²,Hendrie Paul C.¹³,Higman Meghan¹⁴,Hogarty Michael D.¹⁵,Janku Filip¹⁶,Karmali Reem¹⁷,Morgan David¹⁸,Raldow Anne C.¹⁹,Stefanovic Alexandra²⁰,Tantravahi Srinivas K.²¹,Walkovich Kelly²²,Zhang Ling²³,Bergman Mary Anne²⁴,Darlow Susan D.²⁴

Affiliation:

1. 1Mayo Clinic Cancer Center;

2. 2Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center;

3. 3The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;

4. 4Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute Cleveland Clinic Children's Hospital;

5. 5UT Southwestern Simmons Comprehensive Cancer Center;

6. 6St. Jude Children's Research Hospital/The University of Tennessee Health Science Center;

7. 7Fred & Pamela Buffett Cancer Center;

8. 8Memorial Sloan Kettering Cancer Center;

9. 9Yale Cancer Center/Smilow Cancer Hospital;

10. 10UC San Diego Moores Cancer Center;

11. 11O'Neal Comprehensive Cancer Center at UAB;

12. 12Stanford Cancer Institute;

13. 13Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance;

14. 14Roswell Park Comprehensive Cancer Center;

15. 15Abramson Cancer Center at the University of Pennsylvania;

16. 16The University of Texas MD Anderson Cancer Center;

17. 17Robert H. Lurie Comprehensive Cancer Center of Northwestern University;

18. 18Vanderbilt-Ingram Cancer Center;

19. 19UCLA Jonsson Comprehensive Cancer Center;

20. 20Duke Cancer Institute;

21. 21Huntsman Cancer Institute at the University of Utah;

22. 22University of Michigan Rogel Cancer Center;

23. 23Moffitt Cancer Center; and

24. 24National Comprehensive Cancer Network

Abstract

Histiocytic neoplasms are rare hematologic disorders accounting for less than 1% of cancers of the soft tissue and lymph nodes. Clinical presentation and prognosis of these disorders can be highly variable, leading to challenges for diagnosis and optimal management of these patients. Treatment often consists of systemic therapy, and recent studies support use of targeted therapies for patients with these disorders. Observation (“watch and wait”) may be sufficient for select patients with mild disease. These NCCN Guidelines for Histiocytic Neoplasms include recommendations for diagnosis and treatment of adults with the most common histiocytic disorders: Langerhans cell histiocytosis, Erdheim-Chester disease, and Rosai-Dorfman disease.

Publisher

Harborside Press, LLC

Subject

Oncology

Link

https://jnccn.org/downloadpdf/journals/jnccn/19/11/article-p1277.xml

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Blood neurofilament light chain measurements in adults with CNS histiocytic neoplasms;Blood Cancer Journal;2024-09-05

2. Erdheim-Chester Disease Masquerading as CLIPPERS;Neurology Neuroimmunology & Neuroinflammation;2024-09

3. Advancements in the understanding and management of histiocytic neoplasms;Blood Research;2024-07-04

4. Кладрибин в лечении многоочагового мультисистемного гистиоцитоза из клеток Лангерганса у пациента с неблагоприятным прогнозом. Клиническое наблюдение;Clinical Oncohematology;2024-07-01

5. Clinical features and outcomes in primary nervous system histiocytic neoplasms;Blood Cancer Journal;2024-06-20